Research programme: antisense therapies - Ionis Pharmaceuticals

Drug Profile

Research programme: antisense therapies - Ionis Pharmaceuticals

Alternative Names: IONIS EZH2 2.5Rx; IONIS IRF4 2.5Rx; single-stranded RNAi - Ionis; ssRNAi - Ionis

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Ionis Pharmaceuticals; Suzhou Ribo Life Science
  • Class Antisense oligonucleotides; Small interfering RNA
  • Mechanism of Action Protein synthesis inhibitors; RNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Metabolic disorders

Most Recent Events

  • 28 Feb 2018 Preclinical trials of IONIS IRF4 2.5Rx and IONIS EZH2 2.5Rx in Cancer in USA (Parenteral)
  • 28 Feb 2018 Preclinical trials of IONIS EZH2 2.5Rx in Cancer in China (Parenteral)
  • 21 Apr 2017 Early research in Cancer in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top